Estrategias Combinadas en Inmunoterapia Traslacional
ITC
University Hospital Heidelberg
Heidelberg, AlemaniaPublicacións en colaboración con investigadores/as de University Hospital Heidelberg (5)
2022
-
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Journal for immunotherapy of cancer, Vol. 10, Núm. 8
-
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers
ESMO Open, Vol. 7, Núm. 2
2021
-
Type 2 immunity is maintained during cancer-associated adipose tissue wasting
Immunotherapy Advances, Vol. 1, Núm. 1
2015
-
Consensus nomenclature for CD8+ T cell phenotypes in cancer
OncoImmunology, Vol. 4, Núm. 4
2014
-
Classification of current anticancer immunotherapies
Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508